Maarten Boers, EULAR 2022: the GLORIA Trial – Investigating Prednisolone in Rheumatoid Arthritis
touchIMMUNOLOGY were delighted to speak with Prof. Maarten Boers (Amsterdam University Medical Center, Amsterdam, The Netherlands) to discuss the GLORIA trial, investigating the benefits and harms of long term add-on low dose prednisolone in rheumatoid arthritis.
The abstract ‘Favorable balance of benefit and harm of long-term, low dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: The pragmatic, multicenter, placebo- controlled GLORIA trial.’ (Abstract number: OP0263) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What is known about the benefits and harms of long term, low dose glucocorticoid therapy in rheumatoid arthritis (RA), and what questions remain unanswered? (0:18)
- What were the objectives and methodology of the GLORIA trial? (1:22)
- What were the findings of the study in terms of benefits and harms? (1:57)
- What were the conclusions of the investigators regarding future use of add-on low dose prednisolone in RA? (4:14)
- Which patients are most likely to benefit from this approach and in whom is it contraindicated? (5:52)
Disclosures: Maarten Boers discloses consulting for Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
